Sestan Mario, Jelusic Marija
Department of Paediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.
Pediatric Health Med Ther. 2023 Mar 7;14:89-98. doi: 10.2147/PHMT.S379862. eCollection 2023.
IgA vasculitis (IgAV) or Henoch-Schönlein purpura (HSP) is the most common vasculitis in children, and nephritis (IgAVN or HSPN) is the most important and only chronic manifestation of the disease. Despite this, there are no diagnostic criteria and we rely on the European League Against Rheumatism/Paediatric Rheumatology International Trials Organization/Paediatric Rheumatology European Society-endorsed Ankara 2008 classification criteria in our daily practice. Basic investigations that should be done in every patient with IgAVN include blood pressure measurement, estimated glomerular filtration rate and urinalysis. Kidney biopsy is still the gold standard for the diagnosis of IgAVN since noninvasive confirmation of nephritis is still pending. According to the Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) recommendations, the first-line treatment for with mild forms of IgAVN is oral glucocorticoids, for patients with moderate IgAVN parenterally administrated glucocorticoids in pulsed doses, while initial treatment for patients with the most severe forms of IgAVN include pulsed doses of glucocorticoids in combination with intravenous cyclophosphamide pulses. New therapeutic options are currently being tested, aiming to reduce the production of galactose-deficient IgA and autoantibodies or suppress the alternative or lectin complement pathway and blocking mesangial cell activation.
IgA血管炎(IgAV)或过敏性紫癜(HSP)是儿童最常见的血管炎,而肾炎(IgAVN或HSPN)是该疾病最重要且唯一的慢性表现。尽管如此,目前尚无诊断标准,我们在日常实践中依赖欧洲抗风湿病联盟/儿科风湿病国际试验组织/欧洲儿科风湿病学会认可的2008年安卡拉分类标准。每位IgAVN患者都应进行的基本检查包括测量血压、估算肾小球滤过率和尿液分析。由于肾炎的非侵入性确诊仍未解决,肾活检仍是诊断IgAVN的金标准。根据欧洲儿科风湿病单中心及接入点(SHARE)的建议,轻度IgAVN的一线治疗是口服糖皮质激素,中度IgAVN患者采用脉冲剂量的胃肠外给予糖皮质激素,而最严重形式的IgAVN患者的初始治疗包括脉冲剂量的糖皮质激素联合静脉注射环磷酰胺脉冲。目前正在测试新的治疗方案,旨在减少缺乏半乳糖的IgA和自身抗体的产生,或抑制替代或凝集素补体途径并阻断系膜细胞活化。